Local reactogenicity signs and symptoms Throughout study [clinicaltrials_resource:d2acc244d609177a80ad45b12eaeb31f]
Participants will receive a low dose of the adenovirus-vectored HIV vaccine or placebo at study entry
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Local reactogenicity signs and symptoms Throughout study [clinicaltrials_resource:d2acc244d609177a80ad45b12eaeb31f]
Participants will receive a low dose of the adenovirus-vectored HIV vaccine or placebo at study entry
Bio2RDF identifier
d2acc244d609177a80ad45b12eaeb31f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d2acc244d609177a80ad45b12eaeb31f
measure [clinicaltrials_vocabulary:measure]
Local reactogenicity signs and symptoms
time frame [clinicaltrials_vocabulary:time-frame]
Throughout study
description
Participants will receive a lo ...... cine or placebo at study entry
identifier
clinicaltrials_resource:d2acc244d609177a80ad45b12eaeb31f
title
Local reactogenicity signs and symptoms Throughout study
@en
type
label
Local reactogenicity signs and ...... cc244d609177a80ad45b12eaeb31f]
@en